ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / AAPG
OMER (41) NKTR (20) DMRA (35) KRSA (38) ⌘ Pro Terminal →

Ascentage Pharma Group International American Depository Shares (AAPG) — RQD Stock Rating Cockpit

$13.56 -6.20% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.38

Ascentage Pharma Group International American Depository Shares (AAPG) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.35B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AAPG Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AAPG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Ascentage Pharma Group International American Depository Shares (NASDAQ: AAPG) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $13.56 (-6.20% 1D, market cap $1.35B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, AAPG ranks #362 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AAPG compare to OMER and NKTR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AAPG carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, OMER (Omeros Corporation) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B) and NKTR (Nektar Therapeutics) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B). Among the 5-stock peer group, AAPG leads on earnings multiple (N/A) while KRSA leads on capital efficiency (-5.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AAPG?
▼

For Ascentage Pharma Group International American Depository Shares (AAPG), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #362 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $13.38 (-1.31%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510045
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.8% Base Target
$36 Bull$13 Base$10 Bear
📬 FREE AAPG RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AAPG)Realized 20D OHLCV Swing Band: ±6.4%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY AAPG SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (27% of score)

SEC XBRL Trailing 12 Months: 0.9% FCF Margin ($37.8M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
53
Grade C-$15.06+5.7% Next Q
Q2 (-2Q)
50
Grade C-$15.92-6.7% Next Q
Q3 (-1Q)
48
Grade D$14.85-8.7% Next Q
Current
45
Grade D$13.56-6.3% Hist 90D α
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AAPG Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AAPG currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($15.78) and Max Pain ($14.24) forces dealer call-delta covering toward $36.23.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AAPG• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AAPG Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
42.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $14$13.56H: $35
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

Quant Analyst Panel Split (Battleground) on AAPG

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (33)

12/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like AAPG
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AAPG)

  • ✓Walkthrough of AAPG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AAPG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.42%🛡️ HOLDING TREND SUPPORT
2026-11-03O $14.88H $14.88L $13.56C $13.56VOL 15.9K
RES: $16.06SUP: $13.17SMA50: $15.78SMA200: $20.02
$32.67$27.49$22.31$17.13$11.95RES $16.06SUP $13.17$13.562026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AAPG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AAPG Butterfly Map → + Track AAPG →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AAPG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AAPG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AAPG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AAPG)

Health Care Rank #362 of 1015 ⚔️ OMER vs AAPG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AAPG vs. OMER, NKTR, DMRA, KRSA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Ascentage Pharma Group International American Depository Shares (AAPG) ranks #362 by composite RQD confidence (45/100, grade D) and #312 by equity capitalization ($1.35B). Within this direct 5-issuer industry benchmark cohort, AAPG leads on earnings valuation at N/A trailing P/E, while KRSA leads on capital efficiency and profitability with -5.7% ROIC and — gross margin. AAPG currently leads its immediate peer cohort in composite quantitative strength at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AAPG ACTIVE
Ascentage Pharma Group International American Depository Shares
D 45/100 — — — -6.20% $1.35B Benchmark Subject
OMER
Omeros Corporation
D- 41/100 — — -35.0% -3.31% $1.33B /omer-vs-aapg →
NKTR
Nektar Therapeutics
E 20/100 — 96.0% -35.0% -4.94% $1.33B /nktr-vs-aapg →
DMRA
Damora Therapeutics Inc.
D- 35/100 — — -35.0% +0.51% $1.33B /dmra-vs-aapg →
KRSA
Korsana Biosciences Inc.
D- 38/100 — — -5.7% +5.04% $1.37B /krsa-vs-aapg →

2. AAPG Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Ascentage Pharma Group International American Depository Shares (AAPG) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.35B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. AAPG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AAPG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Ascentage Pharma Group International American Depository Shares (NASDAQ: AAPG) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $13.56 (-6.20% 1D, market cap $1.35B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, AAPG ranks #362 in composite RQD confidence.

How does AAPG compare to OMER and NKTR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AAPG carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, OMER (Omeros Corporation) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B) and NKTR (Nektar Therapeutics) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B). Among the 5-stock peer group, AAPG leads on earnings multiple (N/A) while KRSA leads on capital efficiency (-5.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AAPG?

For Ascentage Pharma Group International American Depository Shares (AAPG), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #362 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AAPG trading relative to its 50-day, 200-day, and 52-week technical levels?

AAPG last traded at $13.56 (-6.20% on volume of 5,538 shares), positioning the stock -14.07% below its 50-day simple moving average ($15.78) and -32.27% below its 200-day simple moving average ($20.02). Across its 52-week range of $13.99 to $34.50, AAPG sits at the 0.0% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±6.4% ($12.69 to $14.43).

Direct Sub-Reports: AAPG RQD Cockpit AAPG 12M Forecast AAPG Earnings & Move AAPG Dividends & DRIP AAPG Insiders & 13F AAPG Whale Options AAPG Profit Sankey AAPG News & Why
ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ SEC XBRL & RQD VERIFIED

AAPG — Ascentage Pharma Group International American Depository Shares: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Ascentage Pharma Group International American Depository Shares (AAPG) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $13.56 (-6.20% 1D, market capitalization $1.35B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Ascentage Pharma Group International American Depository Shares (AAPG) operates in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity capitalization of $1.35B, gross margin of —, operating margin of —, and return on invested capital (ROIC) of —.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 45/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $13.99 – $34.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector and industry are listed as Health Care and Biotechnology: Pharmaceutical Preparations. No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are available in source data.

  • Key Question #1: Can AAPG sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $34.50 52-week high?
  • Key Question #3: How sensitive is AAPG's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AAPG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Ascentage Pharma Group International American Depository Shares (AAPG) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AAPG Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AAPG Bull vs. Bear Conversation Board — What's Your Call at $13.56?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AAPG 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AAPG:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $17.93 (+24.0%)
📌 Pinned Debate

Forensic balance sheet scores 13/20 with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5, the strongest pillar in the rating.

Here is why I am bullish on AAPG here at $14.46: Forensic balance sheet scores 13/20 with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5, the strongest pillar in the rating.. Compare AAPG's 0.0% operating margin and 0.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $13.74 are getting bought.

SectorRotator 🐂 BULL

@QuantViper Agree on the RQD 45/100 quality, though with 1.0 beta I'm scaling in with half-size at $14.46 and keeping dry powder in case we test $13.45.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $11.42 (-21.0%)
Spot @ $14.46

Whale 13F flow scores 5/20 with ROIC 0% and FCF yield 0%, pointing to weak institutional accumulation and no cash return on capital.

Whale 13F flow scores 5/20 with ROIC 0% and FCF yield 0%, pointing to weak institutional accumulation and no cash return on capital.. Look at the math on AAPG: paying current EV/EBITDA multiples for 0.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $12.72 before getting long.

LIVE TAPE